In January 2026, the Gates Foundation, the Novo Nordisk Foundation, and Wellcome announced the first grant round of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) consortium: $60 million distributed across 18 research projects in 17 countries, aimed at accelerating early-stage discovery of new antibiotics against Gram-negative bacteria, one of the largest single drivers of antimicrobial-resistance (AMR) deaths worldwide. For grants professionals and research administrators, Gr-ADI is worth tracking less for the dollar figure than for its funding model: it is a rare example of three major biomedical funders co-designing a single consortium with shared data-disclosure terms rather than running parallel, siloed grant programs.
What Gr-ADI actually is
Gr-ADI sits inside a broader $300 million global-health research and development partnership that the Gates Foundation, the Novo Nordisk Foundation, and Wellcome launched in 2024 to fund early-stage discovery work against neglected and drug-resistant diseases. Gr-ADI is described by the three funders as the partnership’s first major investment specifically targeting antibiotic discovery, rather than a separate initiative. The consortium’s stated model is deliberately collaborative rather than competitive: participating research teams are expected to share underlying data and methodological learnings across projects as they go, not just publish results at the end of a grant period, on the premise that pooling early discovery-stage data speeds up a field where individual academic and biotech teams have historically worked in isolation.
Who is funding it, and who runs it
The three funding partners are the Bill & Melinda Gates Foundation, the Novo Nordisk Foundation (Denmark’s largest private foundation, a major funder of biomedical and clinical research), and Wellcome (the UK-based biomedical research charity, see also CASRAI’s overview of how Wellcome’s funding schemes fit together). Day-to-day management and cross-project coordination of the consortium sits with RTI International, an independent nonprofit research institute, which the funders named as the entity responsible for aligning the 18 funded projects, coordinating shared learnings, and keeping the consortium focused on its stated objectives rather than functioning as 18 disconnected grants that happen to share a name.
Scale and scope of the first grant round
- Funding announced: $60 million, described by the funders as the first tranche within the wider $300 million partnership
- Projects funded: 18
- Countries represented: 17, with the funders specifically highlighting support for research teams in low- and middle-income countries alongside teams in traditional biomedical-research hubs
- Funding period: grants are structured to run over roughly three years
- Scientific target: novel approaches to antibiotic discovery against Gram-negative bacteria specifically, a pathogen class (including organisms behind many drug-resistant hospital-acquired infections) that has proven especially difficult for the pharmaceutical pipeline because Gram-negative cell walls block many candidate drug classes that work against Gram-positive bacteria
Why a multi-funder consortium model, rather than three parallel programs
Antibiotic discovery has a well-documented market-failure problem: new antibiotics are expensive and slow to develop, but successful ones are typically used sparingly and briefly (to preserve their effectiveness against resistance), which weakens the commercial return that normally justifies pharmaceutical R&D investment. Philanthropic and public funders have increasingly stepped in to underwrite early discovery-stage work that the commercial pipeline underfunds. What distinguishes Gr-ADI from a foundation simply issuing its own antibiotic-discovery RFP is the explicit multi-funder co-design: a single consortium structure, a shared external manager (RTI International) rather than three separate program offices, and open-data-sharing terms built into participation from the outset rather than negotiated project-by-project after the fact.
For research administrators and grants offices at institutions that may host a Gr-ADI-funded project, this has practical implications distinct from a standard single-funder award: award terms, reporting cadence, and data-sharing obligations are set at the consortium level and may differ from an investigator’s usual Gates, Novo Nordisk, or Wellcome grant agreement. Institutions with existing familiarity with Wellcome’s own open-access and data-sharing requirements, or with the Gates Foundation open-access policy terms, should not assume Gr-ADI’s terms are identical — consortium-level agreements negotiated across three funders are a distinct instrument from any one funder’s standard grant conditions.
How this fits the broader funder-collaboration trend
Gr-ADI is one visible instance of a pattern research-administration offices are seeing more often: major funders co-designing joint initiatives rather than running fully independent programs in the same problem space. For institutions and PIs, the operational upshot is the same regardless of the specific initiative — grants management staff should expect to see more awards where the terms, reporting requirements, and data-governance obligations are set collectively by a funder consortium rather than by a single program officer, and should build in a step to confirm consortium-specific terms rather than defaulting to a funder’s standard award template.
Frequently asked questions
What does Gr-ADI stand for?
Gr-ADI stands for the Gram-Negative Antibiotic Discovery Innovator, the name the Gates Foundation, Novo Nordisk Foundation, and Wellcome gave to this antibiotic-discovery consortium.
Is the $300 million all going to Gr-ADI?
No. The $300 million figure refers to the broader global-health R&D partnership the three funders launched in 2024, of which Gr-ADI is the first major investment. The specific grant round covered here totals $60 million across 18 projects.
Who manages the Gr-ADI consortium day to day?
RTI International, an independent scientific research institute, was named by the funders as the organization coordinating the consortium’s 18 funded projects and aligning them toward shared objectives.
Why does Gr-ADI focus specifically on Gram-negative bacteria?
Gram-negative bacteria have historically been harder to target with new antibiotics than Gram-positive bacteria because their outer cell membrane blocks many drug classes that are otherwise effective, and Gram-negative infections are a major driver of antimicrobial-resistance-associated deaths globally.
What should a grants office do differently for a Gr-ADI-funded project?
Confirm the consortium-level award terms, reporting cadence, and data-sharing obligations directly rather than assuming they match any one funder’s standard agreement — consortium awards negotiated jointly across multiple funders are a distinct instrument from a single-funder grant.
For a broader landscape view of major private and nonprofit biomedical funders, see CASRAI’s guide to private and nonprofit medical research funders.
